Orchestra BioMed (NASDAQ:OBIO – Get Free Report) posted its earnings results on Monday. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01, reports. The business had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $0.89 million.
Orchestra BioMed Price Performance
NASDAQ:OBIO opened at $7.12 on Thursday. The firm has a 50 day simple moving average of $6.39 and a 200-day simple moving average of $8.70. Orchestra BioMed has a 1-year low of $4.26 and a 1-year high of $23.39.
Analyst Upgrades and Downgrades
Separately, Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a research report on Wednesday, August 9th.
Institutional Trading of Orchestra BioMed
Several institutional investors have recently made changes to their positions in OBIO. RTW Investments LP acquired a new position in shares of Orchestra BioMed in the 1st quarter valued at approximately $100,169,000. Perceptive Advisors LLC bought a new position in shares of Orchestra BioMed in the first quarter valued at approximately $44,585,000. BlackRock Inc. bought a new position in shares of Orchestra BioMed in the first quarter valued at $13,790,000. Boxer Capital LLC purchased a new stake in Orchestra BioMed during the first quarter valued at about $4,893,000. Finally, Geode Capital Management LLC purchased a new position in Orchestra BioMed during the 1st quarter valued at about $2,446,000. 30.16% of the stock is owned by hedge funds and other institutional investors.
Orchestra BioMed Company Profile
Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
- Five stocks we like better than Orchestra BioMed
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Unlocking AI investment opportunities in healthcare
- How to Invest in Fertilizer
- New Disney investor propels stock to ranks of best S&P gainers
- How to Buy Cheap Stocks Step by Step
- Buffett’s latest portfolio additions, trims, and cuts in Q3
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.